Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Income towards Parent Company: 2022-2024

Historic Income towards Parent Company for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to -$204.7 million.

  • Day One Biopharmaceuticals' Income towards Parent Company fell 154.94% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.7 million, marking a year-over-year increase of 21.59%. This contributed to the annual value of -$204.7 million for FY2024, which is 8.38% down from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Income towards Parent Company of -$204.7 million as of FY2024, which was down 8.38% from -$188.9 million recorded in FY2023.
  • Over the past 5 years, Day One Biopharmaceuticals' Income towards Parent Company peaked at -$142.2 million during FY2022, and registered a low of -$204.7 million during FY2024.
  • Moreover, its 3-year median value for Income towards Parent Company was -$188.9 million (2023), whereas its average is -$178.6 million.
  • Data for Day One Biopharmaceuticals' Income towards Parent Company shows a maximum YoY plummeted of 32.86% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Day One Biopharmaceuticals' Income towards Parent Company stood at -$142.2 million in 2022, then plummeted by 32.86% to -$188.9 million in 2023, then fell by 8.38% to -$204.7 million in 2024.